I don’t know why you would bother looking at any other stock

This stock checks all of the boxes for me right now. I am excited to see how it closes out the week. *Sponsored by Sica Media I have been pounding the table on the market reversal and that has certainly happened this week. That has led to a phenomenal week of trading, and I am looking to close out Friday strong as I head into the long weekend – I hope you are too! Right now, I want to bring your attention to what I honestly feel is the only stock you should be looking at today. If you recall, I discussed this stock about a week ago, and said that I thought it was a great candidate for a reversal play:  NLS Pharmaceutics AG (Nasdaq: NLSP) At that time, the stock was purely a “technical breakout” idea. The stock had been trading in a very tight range for nearly a month and the setup was perfect, I thought at least, for a breakout at some point. NLSP did in fact make a double-digit move higher, and then consolidated one more time before making a clear breakout move higher, this time over 20% as it finally got back above $1 yesterday. While the price move has been great, it’s what the company quietly announced this week that really has my attention. You see, NLSP is not a high-profile stock, and they don’t do a good job of “tooting their own horn,” so to speak. Not a lot of analysts cover it (but those that do have an average price target nearly 400% higher from current levels!) and a few days ago the company dropped what I thought was a bombshell, buried inside of a non-descript [press release](. Here is what I found especially fascinating from the release they issued: ‘’At this time we have received several non-binding term sheets for a potential partnership agreement within the pharmaceutical industry. The Company is still in negotiations, has not executed a definitive agreement, and no party is under any obligation to enter into or continue negotiations regarding a definitive agreement related to any transaction.’’ They literally have interest in hand from other pharmaceutical companies looking to “partner” with them. From my experience, other major pharma players like to form partnerships with companies that are in Phase 3 trials because if the trial is successful, then there is a brand new drug approved and ready to go to market. Sure, it drives up the stock price a lot (good for shareholders of the company being acquired) if the company is successful in Phase 3, but the larger company is buying an asset that has very low risk at that point. If you read the reports, NLSP’s initial data is amazing. Right now, it looks like they have plenty of options to pick which partner would be the right fit for their Phase 3 trial. NLSP also dropped this in their release which I thought went totally under the radar of most investors… ‘’On August 25, 2023, NLSP submitted a fast-track designation application for Mazindol ER for the treatment of narcolepsy to the FDA.” From the [FDA’s website](, we can read that, “Fast track is a designation by the FDA of an investigational drug for expedited review to facilitate development of drugs that treat a serious or life-threatening condition and fill an unmet medical need. A drug may be granted Fast Track Designation if it is believed to have an impact on patient survival, day-to-day functioning, or if it is believed that the condition will progress in severity if left untreated. Standard reviews by the FDA for drug approval generally take about one year. A medicine that receives Fast Track Designation can be on the market within six months of the regulatory application.’’ There are no guarantees, of course, but from what I read above, “Fast track drugs” can be on the market in 6 months from the regulatory application! Folks, we are on the cusp of what I feel is something really big here. NLSP is no longer just a “reversal play.” There are so many catalysts around this stock right now that it would be absolutely foolish for you not to dig in and do your own research on the opportunity right now. I think it is late in the game to try and pick a big cap tech stock to trade right today. Instead, my bet is on small stocks that have truly huge upside potential from here.  And for me, I think NLSP fits the bill perfectly. So what does NLS Pharmaceutics (NLSP) do? NLSP is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system (CNS) disorders. Worldwide, [over three million people]( are challenged by narcolepsy — an inability to regulate sleep-wake cycles. In the United States alone, [11 percent of children]( between four and eleven years old are distressed by a form of ADHD, creating a heavy burden on the individual, their families, and society as a whole. NLSP is seeking to address these markets and meet their needs. The proprietary drugs they’re releasing are poised to dominate the global narcolepsy drugs market that’s projected to reach over [$6.6 BILLION by 2030](! And just yesterday, the stock closed just over $1, the first time since July– but what do analysts have to say? The analysts that cover it forecast NLSP to trade anywhere from $4 on the low side up to $6 on the higher side, as you can see on this chart from the [Wall Street Journal](… And, frankly, it’s not hard to see why. The company has a long track record of success that puts them [more than three times ahead]( of their nearest competitor… And their proprietary Mazidol treatment could be the key to their total domination of the sector. As it stands, Narcolepsy lacks what’s called a “monotherapy” — a one-step treatment, and most patients are treated with a cocktail of drugs that includes numerous Schedule I and II substances, including GHB (also known as the date rape drug). This has left 94% of patients with the belief that a new, innovative, and safer means of treating narcolepsy is required. That’s where Mazidol comes in… It’s a drug with a 30-year history of commercial use in the U.S. and Europe as an appetite suppressant under the name “Sanorex,” and it’s been used in Europe for nearly 40 years as an off-label treatment. For those of you who don’t know, an “off-label” treatment is one that a doctor prescribes for a use that the drug isn’t necessarily intended for. But now, NLSP is taking Mazidol into prime time as they undergo Phase 3 clinical trials, a process which we’ve seen lead to massive momentum for biotech stocks (as we saw during the Pandemic). Like when AstraZeneca (AZN) launched clinical trials for a COVID vaccine — Investors who jumped in before the trial went live were capable of snatching up a 55% gain — in just three months! They say history doesn’t always repeat itself, but it often rhymes. And since we’ve witnessed this same story play out like clockwork over the years… I can’t stress enough how important the Phase 3 trial is for NLSP. This is the final leg of the journey when it comes to receiving full FDA approval for a drug, and if that is successful? The rewards for shareholders could be massive. Receiving the trial authorization could be the start of a runup for NLSP, as we have already seen over the last few days. If all continues to go well, a series of successful drug trials is capable of sending this stock into overdrive. But it’s not just about the product, or the testing — it’s about the leadership behind this organization. [Its roster of heavy hitters]( is absolutely stunning, and gives me a huge boost of confidence in their potential to make waves in the sector. Leadership’s wide range of expertise has landed NLSP partnerships with some of the top narcolepsy research institutions in the world, including: - Université de Lausanne (UNIL) (preclinical projects) - University of Berne (narcolepsy research), Swiss Narcolepsy Network (narcolepsy research) -  (BVF Partners L.P (financial partnership) - Narcolepsy Network - The Narcolepsy Foundation - The Sleep Consortium - Hypersomnia Foundation - Wake Up Narcolepsy But just because I (and all of these institutions) love this stock doesn’t mean you have to.  It’s critical that you do your own research before deciding if NLSP is right for your portfolio, and a great place to start would be right here at [the company’s website.]( This is an urgent situation, so make sure you look into NLSP right away. To YOUR Success! P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of my latest HOT STOCK ideas! *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Manage your email subscriptions.]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. If you have a current active subscription with Bullseye Trades you will need to contact us if you want to cancel your subscription. Opting out of emails does not remove you from your service at Bullseye Trades.